Last week, President Obama released his federal budget proposal for fiscal year 2013. While this document does not by itself dictate policy, it outlines the President’s priority areas and lays the groundwork for the budget debate to come.

Like many in the brain tumor and cancer communities, we were left scratching our heads after reading the proposal. The President has talked the talk when it comes to our priority issues. In 2009, he made a commitment to finding a cure for cancer in our lifetime during the State of the Union address. And just a few weeks ago, he again used the State of the Union to show support, touting the advances that federally funded research is making in the search for a cure.

After the National Institutes of Health (NIH) and the National Cancer Institute (NCI) both received an increase in funding last December - thanks to your advocacy - we had reason to be hopeful that we’d see continued progress this year.

But with this new budget proposal, the Obama administration is showing that they aren’t ready to walk the walk. The FY13 budget proposal keeps NIH at 2012 funding levels and cuts funding for NCI, which could prove detrimental to current progress toward new treatments and, ultimately, a cure.

We know that times are tough and but brain tumor patients and caregivers face a life-threatening disease. Cutting research funding in one year can derail progress for many years. As the federal budget is squeezed tighter, a growing number of interests will clamor to be heard by decision-makers in Washington, DC. We can’t let our voices get lost in the din. We need to rise above the noise, louder than ever, and let the President and Members of Congress know that a cure can’t wait.

Researchers at the St. Jude Children’s Research Hospital and the Washington University Pediatric Cancer Genome Project have linked gene mutations not previously tied to cancer to the rare but deadly brain tumor diffuse intrinsic pontine glioma (DIPG). DIPG accounts for 10% to 15% of pediatric tumors of the brain and central nervous system. It aggressively attacks the brainstem and kills more than 90% of its victims within two years.

“We are hopeful that identifying these mutations will lead us to new selective therapeutic targets, which are particularly important since this tumor cannot be treated surgically and still lacks effective therapies,” Suzanne Baker, PhD, corresponding author of the January 29 paper in Nature Genetics and co-leader of the St. Jude Neurology and Brain Tumor Program, said in a statement. She holds the Sydney Schlobohm Chair of Research funded by the National Brain Tumor Society and is a member of the NBTS Scientific Advisory Council.

Dr. Baker and colleagues, in research partially funded by the NBTS, discovered that specific mutations in the HRF3A and HIST1H3B genes existed in almost 80% of the DIPG tumors they studied. These gene mutations also were present in pediatric glioblastoma tumors they studied, but not in other tumor types.

These genes encode histone proteins that organize the structure of DNA in cells and regulate how genes are expressed. In the pediatric tumor cells, their mutation is thought to interfere with these functions. The researchers are now trying to determine how the mutations are involved in development of these pediatric tumors.

The Pediatric Cancer Genome Project is an ambitious three-year project to sequence the normal and cancer genomes of 600 children with poorly understood, aggressive pediatric cancers, with the goal of finding new tools to diagnose, treat, or prevent diseases.